Clinical trial of simvastatin tablet combined with clopidogrel bisulfate tablet in the treatment of unstable angina pectoris
Ling LIN,Wu-jian HE,Shi-qi LU,Fang HUANG
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2017.22.003
2017-01-01
Abstract:Objective To observe the clinical efficacy and safety profile of simvastatin combined with clopidogrel bisulfate in the treatment of unstable angina pectoris (UAP).Methods A total of 107 UAP patients were randomly divided into treatment group (n =53) and control group (n =54).Both groups were given conventional treatment.The control group received oral administration of simvastatin 40 mg once daily,while the treatment group received oral administration of clopidogrel bisulfate (initiated with a single 300 mg loading dose and then continued at 75 mg once a day) on the basis of control group.The total effective rate,hemorheology,the level of Fractalkine,monocyte chemoattractant protein-1 (MCP-1),quality of life scores (QOL) and adverse drug reactions were compared between the two groups after 6-month treatment.Results The total effective rates of the treatment group and the control group were 90.57% (48 cases/53 cases) and 74.07% (40 cases/54 cases) respectively,the difference was statistically significant (P < 0.05).After treatment,the fibrinogen level in the treatment group and the control group were (3.96 ± 0.63),(4.52 ± 0.64) g · L-1,the plasma viscosity were (1.66 ±0.21),(1.81 ± 0.23) mPa · s,the erythrocyte aggregation indices were 2.89 ± 0.41,3.84 ± 0.39,the erythrocyte sedimentation rates were respectively (23.13 ± 7.35),(25.05 ± 7.01)mm · h-1,the platelet aggregation rates were respectively (38.79 ± 2.87) %,(42.79 ± 3.17) %,the Fractalkine were (34.74 ± 5.82),(40.42 ± 6.13)ng · L-1,the MCP-1 were (43.16 ±5.61),(48.89 ±6.29) ng· L-1,respectively,and the differences between the treatment group and the control group were statistically significant (P <0.05).The drug adverse reactions of the two groups were elevated liver transaminase,gastrointestinal reaction and skin purpura,the adverse drug reactions in the treatment group and the control group were 9.43% (5 cases/53 cases) and 9.25% (5 cases/54 cases),respectively,with no statistically significant difference (P >0.05).Conclusion Simvastatin combined with clopidogrel bisulfate could effectively improve the hemorheology and reduce the level of Fractalkine and MCP-1 in UAP patients,with satisfying safety profile.